Iterum Therapeutics Plc Stock Performance
| ITRM Stock | USD 1.81 0.04 2.26% |
Iterum Therapeutics holds a performance score of 9 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -1.57, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Iterum Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Iterum Therapeutics is expected to outperform it. Use Iterum Therapeutics PLC jensen alpha, skewness, relative strength index, as well as the relationship between the value at risk and day median price , to analyze future returns on Iterum Therapeutics PLC.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Iterum Therapeutics PLC are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Iterum Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:15 | Last Split Date 2022-08-18 |
1 | Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women | 09/10/2024 |
2 | Disposition of 15000 shares by Ahrens Brenton Karl of Iterum Therapeutics at 2.0181 subject to Rule 16b-3 | 09/16/2024 |
3 | Acquisition by Hunt Ronald of 65481 shares of Iterum Therapeutics at 1.21 subject to Rule 16b-3 | 09/27/2024 |
4 | Iterum Therapeutics shareholders approve share issuance authority - Investing.com | 10/08/2024 |
5 | Iterum Therapeutics plc Short Interest Update | 10/14/2024 |
6 | Acquisition by Dunne Michael W. of 106247 shares of Iterum Therapeutics at 1.21 subject to Rule 16b-3 | 10/17/2024 |
7 | Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH for the Treatment of Uncomplicated Urinary Tract Infections | 10/25/2024 |
8 | FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships | 10/28/2024 |
9 | Iterum Therapeutics defers 20 million FDA milestone payment - Investing.com | 11/01/2024 |
10 | Acquisition by Ahrens Brenton Karl of 113276 shares of Iterum Therapeutics at 0.2 subject to Rule 16b-3 | 11/05/2024 |
11 | Iterum Therapeutics Non-GAAP EPS of -0.24 misses by 0.03 | 11/14/2024 |
12 | Iterum Therapeutics Regains Full Nasdaq Compliance | 11/21/2024 |
| Begin Period Cash Flow | 21.1 M |
Iterum |
Iterum Therapeutics Relative Risk vs. Return Landscape
If you would invest 112.00 in Iterum Therapeutics PLC on August 27, 2024 and sell it today you would earn a total of 69.00 from holding Iterum Therapeutics PLC or generate 61.61% return on investment over 90 days. Iterum Therapeutics PLC is currently generating 1.1398% in daily expected returns and assumes 9.6042% risk (volatility on return distribution) over the 90 days horizon. In different words, 85% of stocks are less volatile than Iterum, and 78% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Iterum Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Iterum Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Iterum Therapeutics PLC, and traders can use it to determine the average amount a Iterum Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1187
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ITRM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.6 actual daily | 85 85% of assets are less volatile |
Expected Return
| 1.14 actual daily | 22 78% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Iterum Therapeutics is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Iterum Therapeutics by adding it to a well-diversified portfolio.
Iterum Therapeutics Fundamentals Growth
Iterum Stock prices reflect investors' perceptions of the future prospects and financial health of Iterum Therapeutics, and Iterum Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Iterum Stock performance.
| Return On Equity | -5.56 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 57.74 M | ||||
| Shares Outstanding | 27.52 M | ||||
| Price To Earning | 16.21 X | ||||
| Price To Book | 6.03 X | ||||
| Price To Sales | 1,350 X | ||||
| Gross Profit | 37 K | ||||
| EBITDA | (34.58 M) | ||||
| Net Income | (38.37 M) | ||||
| Cash And Equivalents | 68.91 M | ||||
| Cash Per Share | 5.63 X | ||||
| Total Debt | 18.96 M | ||||
| Debt To Equity | 0.58 % | ||||
| Current Ratio | 9.47 X | ||||
| Book Value Per Share | (0.47) X | ||||
| Cash Flow From Operations | (39.33 M) | ||||
| Earnings Per Share | (1.76) X | ||||
| Market Capitalization | 49.8 M | ||||
| Total Asset | 26.26 M | ||||
| Retained Earnings | (461.3 M) | ||||
| Working Capital | 12.08 M | ||||
| Current Asset | 36.86 M | ||||
| Current Liabilities | 5.97 M | ||||
About Iterum Therapeutics Performance
By examining Iterum Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Iterum Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Iterum Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (337.81) | (354.70) | |
| Return On Tangible Assets | (1.46) | (1.53) | |
| Return On Capital Employed | (3.73) | (3.54) | |
| Return On Assets | (1.46) | (1.53) | |
| Return On Equity | 5.99 | 6.29 |
Things to note about Iterum Therapeutics PLC performance evaluation
Checking the ongoing alerts about Iterum Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Iterum Therapeutics PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Iterum Therapeutics is way too risky over 90 days horizon | |
| Iterum Therapeutics may become a speculative penny stock | |
| Iterum Therapeutics appears to be risky and price may revert if volatility continues | |
| Iterum Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (38.37 M) with profit before overhead, payroll, taxes, and interest of 37 K. | |
| Iterum Therapeutics PLC currently holds about 68.91 M in cash with (39.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Iterum Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Iterum Therapeutics Regains Full Nasdaq Compliance |
- Analyzing Iterum Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Iterum Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Iterum Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Iterum Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Iterum Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Iterum Therapeutics' stock. These opinions can provide insight into Iterum Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (5.56) |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.